These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34433022)

  • 1. Gain-of-function p53
    Siolas D; Vucic E; Kurz E; Hajdu C; Bar-Sagi D
    Cell Rep; 2021 Aug; 36(8):109578. PubMed ID: 34433022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2
    Xie Y; Zhou T; Li X; Zhao K; Bai W; Hou X; Liu Z; Ni B; Zhang Z; Yan J; Wang Y; Jiang W; Wang H; Chang A; Gao S; Zhao T; Yang S; Huang C; Liu J; Hao J
    Gastroenterology; 2024 Jul; 167(2):281-297. PubMed ID: 38492894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.
    Keenan BP; Saenger Y; Kafrouni MI; Leubner A; Lauer P; Maitra A; Rucki AA; Gunderson AJ; Coussens LM; Brockstedt DG; Dubensky TW; Hassan R; Armstrong TD; Jaffee EM
    Gastroenterology; 2014 Jun; 146(7):1784-94.e6. PubMed ID: 24607504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Cell Analysis Differentiates the Effects of p53 Mutation and p53 Loss on Cell Compositions of Oncogenic Kras-Driven Pancreatic Cancer.
    Sun X; Yang D; Chen Y
    Cells; 2023 Nov; 12(22):. PubMed ID: 37998349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
    Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
    Ogawa S; Fukuda A; Matsumoto Y; Hanyu Y; Sono M; Fukunaga Y; Masuda T; Araki O; Nagao M; Yoshikawa T; Goto N; Hiramatsu Y; Tsuda M; Maruno T; Nakanishi Y; Hussein MS; Tsuruyama T; Takaori K; Uemoto S; Seno H
    Gastroenterology; 2020 Aug; 159(2):682-696.e13. PubMed ID: 32360551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma.
    Lakshmanan I; Marimuthu S; Chaudhary S; Seshacharyulu P; Rachagani S; Muniyan S; Chirravuri-Venkata R; Atri P; Rauth S; Nimmakayala RK; Siddiqui JA; Gautam SK; Shah A; Natarajan G; Parte S; Bhyravbhatla N; Mallya K; Haridas D; Talmon GA; Smith LM; Kumar S; Ganti AK; Jain M; Ponnusamy MP; Batra SK
    Oncogene; 2022 Nov; 41(48):5147-5159. PubMed ID: 36271032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
    Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
    Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
    Tiwari A; Tashiro K; Dixit A; Soni A; Vogel K; Hall B; Shafqat I; Slaughter J; Param N; Le A; Saunders E; Paithane U; Garcia G; Campos AR; Zettervall J; Carlson M; Starr TK; Marahrens Y; Deshpande AJ; Commisso C; Provenzano PP; Bagchi A
    Gastroenterology; 2020 Nov; 159(5):1882-1897.e5. PubMed ID: 32768595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.
    Lee JW; Komar CA; Bengsch F; Graham K; Beatty GL
    Curr Protoc Pharmacol; 2016 Jun; 73():14.39.1-14.39.20. PubMed ID: 27248578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
    Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
    EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
    Chao T; Furth EE; Vonderheide RH
    Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pericyte stem cells induce Ly6G
    Wu Z; Thierry K; Bachy S; Zhang X; Gamradt P; Hernandez-Vargas H; Mikaelian I; Tonon L; Pommier R; Zhao Y; Bertolino P; Hennino A
    EMBO Rep; 2023 Apr; 24(4):e56524. PubMed ID: 36802267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones.
    Ren YA; Mullany LK; Liu Z; Herron AJ; Wong KK; Richards JS
    Cancer Res; 2016 Apr; 76(8):2206-18. PubMed ID: 26964623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.
    Feldmann G; Karikari C; dal Molin M; Duringer S; Volkmann P; Bartsch DK; Bisht S; Koorstra JB; Brossart P; Maitra A; Fendrich V
    Cancer Biol Ther; 2011 Jun; 11(11):959-68. PubMed ID: 21455033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy.
    Horvat NK; Karpovsky I; Phillips M; Wyatt MM; Hall MA; Herting CJ; Hammons J; Mahdi Z; Moffitt RA; Paulos CM; Lesinski GB
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38191243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.